123 related articles for article (PubMed ID: 38496627)
21. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
[TBL] [Abstract][Full Text] [Related]
22. FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer.
Seachrist DD; Anstine LJ; Keri RA
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680352
[TBL] [Abstract][Full Text] [Related]
23. Isolation and characterization of a new basal-like luminal progenitor in human breast tissue.
Bhat V; Lee-Wing V; Hu P; Raouf A
Stem Cell Res Ther; 2019 Aug; 10(1):269. PubMed ID: 31443683
[TBL] [Abstract][Full Text] [Related]
24. In Vivo Application of CRISPR/Cas9 Revealed Implication of
Cai H; Agersnap SN; Sjøgren A; Simonsen MK; Blaavand MS; Jensen UV; Thomsen MK
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139541
[TBL] [Abstract][Full Text] [Related]
25. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.
Gerhardt J; Montani M; Wild P; Beer M; Huber F; Hermanns T; Müntener M; Kristiansen G
Am J Pathol; 2012 Feb; 180(2):848-61. PubMed ID: 22138582
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
27. Frequent mutation of the
Annala M; Taavitsainen S; Vandekerkhove G; Bacon JVW; Beja K; Chi KN; Nykter M; Wyatt AW
Commun Biol; 2018; 1():122. PubMed ID: 30272002
[TBL] [Abstract][Full Text] [Related]
28. Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer.
Helminen L; Huttunen J; Tulonen M; Aaltonen N; Niskanen EA; Palvimo JJ; Paakinaho V
Nucleic Acids Res; 2024 Jan; 52(2):625-642. PubMed ID: 38015476
[TBL] [Abstract][Full Text] [Related]
29. FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype.
DeGraff DJ; Grabowska MM; Case TC; Yu X; Herrick MK; Hayward WJ; Strand DW; Cates JM; Hayward SW; Gao N; Walter MA; Buttyan R; Yi Y; Kaestner KH; Matusik RJ
Lab Invest; 2014 Jul; 94(7):726-39. PubMed ID: 24840332
[TBL] [Abstract][Full Text] [Related]
30. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
Jin HJ; Zhao JC; Wu L; Kim J; Yu J
Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
[TBL] [Abstract][Full Text] [Related]
31. Lysosome-dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer.
Celada SI; Li G; Celada LJ; Lu W; Kanagasabai T; Feng W; Cao Z; Salsabeel N; Mao N; Brown LK; Mark ZA; Izban MG; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Wang X; Chen Z
Mol Oncol; 2023 Oct; 17(10):2126-2146. PubMed ID: 37491794
[TBL] [Abstract][Full Text] [Related]
32. FOXA1 in prostate cancer.
Dong HY; Ding L; Zhou TR; Yan T; Li J; Liang C
Asian J Androl; 2023; 25(3):287-295. PubMed ID: 36018068
[TBL] [Abstract][Full Text] [Related]
33. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.
Zhou S; Hawley JR; Soares F; Grillo G; Teng M; Madani Tonekaboni SA; Hua JT; Kron KJ; Mazrooei P; Ahmed M; Arlidge C; Yun HY; Livingstone J; Huang V; Yamaguchi TN; Espiritu SMG; Zhu Y; Severson TM; Murison A; Cameron S; Zwart W; van der Kwast T; Pugh TJ; Fraser M; Boutros PC; Bristow RG; He HH; Lupien M
Nat Commun; 2020 Jan; 11(1):441. PubMed ID: 31974375
[TBL] [Abstract][Full Text] [Related]
34. Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression.
Song B; Park SH; Zhao JC; Fong KW; Li S; Lee Y; Yang YA; Sridhar S; Lu X; Abdulkadir SA; Vessella RL; Morrissey C; Kuzel TM; Catalona W; Yang X; Yu J
J Clin Invest; 2019 Feb; 129(2):569-582. PubMed ID: 30511964
[TBL] [Abstract][Full Text] [Related]
35. Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia.
Grabowska MM; Kelly SM; Reese AL; Cates JM; Case TC; Zhang J; DeGraff DJ; Strand DW; Miller NL; Clark PE; Hayward SW; Gronostajski RM; Anderson PD; Matusik RJ
Endocrinology; 2016 Mar; 157(3):1094-109. PubMed ID: 26677878
[TBL] [Abstract][Full Text] [Related]
36. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.
Robinson JL; Hickey TE; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Neal DE; Tilley WD; Carroll JS
Oncogene; 2014 Dec; 33(50):5666-74. PubMed ID: 24292680
[TBL] [Abstract][Full Text] [Related]
37. An Organoid Assay for Long-Term Maintenance and Propagation of Mouse Prostate Luminal Epithelial Progenitors and Cancer Cells.
Shu Y; Chua CW
Methods Mol Biol; 2019; 1940():231-254. PubMed ID: 30788830
[TBL] [Abstract][Full Text] [Related]
38. Urethral luminal epithelia are castration-insensitive cells of the proximal prostate.
Joseph DB; Henry GH; Malewska A; Iqbal NS; Ruetten HM; Turco AE; Abler LL; Sandhu SK; Cadena MT; Malladi VS; Reese JC; Mauck RJ; Gahan JC; Hutchinson RC; Roehrborn CG; Baker LA; Vezina CM; Strand DW
Prostate; 2020 Aug; 80(11):872-884. PubMed ID: 32497356
[TBL] [Abstract][Full Text] [Related]
39. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
[TBL] [Abstract][Full Text] [Related]
40. A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer.
Dorso M; Patel PT; Pankov A; Boyer JA; Soni RK; Del Priore IS; Hayatt O; Kulick A; Hagen CJ; de Stanchina E; Junttila MR; Daemen A; Friedman LS; Hendrickson RC; Chandarlapaty S
Cancer Res Commun; 2023 Sep; 3(9):1788-1799. PubMed ID: 37691854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
